Healthcare · NSE: METROPOLIS
Metropolis Healthcare
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 4 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹11,907Cr
- P/E
- 53.1×
- 1Y return
- +16.53%
- From 52W high
- −5.7%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 497 | 429 | +15.8% | 450 | +10.4% |
| EBITDA | 134 | 108 | +23.8% | 111 | +20.5% |
| EBITDA margin | 27.0% | 25.2% | +176 bps | 24.7% | +228 bps |
| PBTProfit before tax | 102 | 71 | +44.3% | 78 | +31.9% |
| Net profit | 75 | 53 | +43.0% | 57 | +32.9% |
| EPS (₹) | 3.60 | 10.13 | -64.5% | 2.73 | +31.9% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Similar growth and margin trajectory expected for rest of the year
Ameera Shah · Chairperson and Whole · p. 3
Similar growth and margin trajectory expected for rest of the year
“As we move forward, we are optimistic of continuing similar growth and margin trajectory for the rest of the year.”
More figures from the call
“Network density is increasing as we add centers around existing labs, taking our center-to-lab ratio from 24:1 towards 30:1 and then 35:1 over the next 2 years.”
“And we said that we will take this up to maybe close to 30 by the end of this year and then maybe end of next year to a 30:1 to 35:1 ratio.”
“So we did mention in the past that our capex will be in the range of 4% to 5% overall, right?”
“See, one is we have stopped adding any more new labs, and we stay put with 750 towns for operations, right?”
“During the quarter, we added 116 collection centers, taking our net additions to 700 over the last 24 months.”
“well ahead of our guidance of 125 to 170 basis points. This improvement came from volume-led operating leverage, disciplined cost management and steady progress on our productivity agenda.”
In short
- 01Management expects H1 trends of about 16% revenue growth and 180 to 200 bps margin gain to continue for the rest of FY27.
- 02Q2 FY27 revenue was Rs 497 crore, up 16%; EBITDA margin rose 180 bps to 27.2%; PAT was Rs 75 crore, up 43%.
- 03A price increase for part of the business, B2C for now, is planned for Q4 or early next year.
- 04Management sees room to improve margins by 125 to 150 bps in the coming years.
- 05Capex is expected at about Rs 65 to 70 crore this year; no new labs are being added.
- 06Specialty and TruHealth each grew 20%; Tier 3 and rural centers grew about 20%.
- 07IRR on the Core Diagnostics acquisition is estimated at about 13%; Core reached double-digit margin last quarter.
- 08An interim dividend of Rs 1 per share was declared.
Segments
B2C: Existing centers delivered same-store growth of 10%
Surendran Chemmenkotil · Managing Director · p. 8
B2C: Existing centers delivered same-store growth of 10%
“Growth was broad-based across both mature and newer centers with existing centers delivering same-store growth of 10% and improved retail productivity, while newer centers continue to ramp up.”
B2B: B2B business grew 15%
Surendran Chemmenkotil · Managing Director · p. 8
B2B: B2B business grew 15%
“Our B2B business grew 15%, reflecting our focused approach of partnering with hospitals, clinicians and quality-led institutions where our science expertise and specialty portfolio give us a clear edge.”
B2B: B2B patient volume up 7%, test volume up 11%
Surendran Chemmenkotil · Managing Director · p. 8
B2B: B2B patient volume up 7%, test volume up 11%
“Within B2B, patient volume grew by 7% and test volume grew by 11% which means partners are sending us more tests per patient, a clear sign of growing wallet share.”
B2B: B2B partner network crossed 9,000 partners
Surendran Chemmenkotil · Managing Director · p. 8
B2B: B2B partner network crossed 9,000 partners
“We continue to add new lab and hospital partnership during the quarter, and B2B partner network has now crossed 9,000 partners.”
TruHealth and Specialty: TruHealth 17% of revenue, Specialty 40%; both grew 20% in Q2
Sameer Patel · Chief Financial Officer · p. 10
TruHealth and Specialty: TruHealth 17% of revenue, Specialty 40%; both grew 20% in Q2
“TruHealth contributed 17% of revenue and grew 20% on a year-on-year basis, while Specialty contributed 40% of revenue and grew 20% on a year-on-year basis.”
Demand
Patient volumes grew 10%, test volume around 11%
Surendran Chemmenkotil · Managing Director · p. 7
Patient volumes grew 10%, test volume around 11%
“Patient volumes grew by 10% and test volume around 11% with the balance coming from a richer test mix and better realization.”
Unclear if hospital price pressure leads to more test outsourcing
Ameera Shah · Chairperson and Whole · Q&A · p. 19
Unclear if hospital price pressure leads to more test outsourcing
“Now whether that results in more outsourcing of tests, I think we'll have to wait and watch.”
Tier 2, Tier 3 towns: New centers and labs in Tier 2 and Tier 3 towns becoming productive
Surendran Chemmenkotil · Managing Director · Q&A · p. 19
Tier 2, Tier 3 towns: New centers and labs in Tier 2 and Tier 3 towns becoming productive
“One is all the new centers and the labs that we put up over the last, let's say, a couple of years in the Tier 2, Tier 3 towns are all becoming productive.”
Smaller unorganised players seen shutting down as quality and specialty testing grow
Ameera Shah · Chairperson and Whole · Q&A · p. 13
Smaller unorganised players seen shutting down as quality and specialty testing grow
“And we've been seeing that happening over the last few years, even without government regulation that as quality comes to the fore, as consumers become more conscious, as specialized testing increases, which the unorganized guys can't do, we have seen smaller players shut down and not be able to operate in the market.”
B2B hospitals: More hospital outsourcing of tests they already run in-house seen as unlikely
Surendran Chemmenkotil · Managing Director · Q&A · p. 18
B2B hospitals: More hospital outsourcing of tests they already run in-house seen as unlikely
“But whether there's an opportunity for them not to do some of the tests and I mean outsource to us, I mean, that's unlikely because they already have the lab and arrangements there.”
Margins and costs
H1 EBITDA margin up 190 bps to 26.2%, without any price increase
Ameera Shah · Chairperson and Whole · p. 3
H1 EBITDA margin up 190 bps to 26.2%, without any price increase
“Importantly, we have delivered the step-up in growth while expanding EBITDA margins by 190 basis points to 26.2% EBITDA margin for the first half, and this is without any price increase so far in the year.”
Q2 EBITDA Rs 135 crore, up 24% year-on-year
Sameer Patel · Chief Financial Officer · p. 10
Q2 EBITDA Rs 135 crore, up 24% year-on-year
“With respect to quarter 2 margin, EBITDA stood at INR135 crores, growing 24% year-on-year.”
Q2 EBITDA margin up 180 bps to 27.2%; PAT Rs 75 crore, up 43%
Sameer Patel · Chief Financial Officer · p. 10
Q2 EBITDA margin up 180 bps to 27.2%; PAT Rs 75 crore, up 43%
“EBITDA margin expanded 180 basis points to 27.2%. PAT stood at INR75 crores, growing at 43% year-on-year.”
Q2 PAT margin up 290 bps to 15.2%, highest post-COVID
Sameer Patel · Chief Financial Officer · p. 10
Q2 PAT margin up 290 bps to 15.2%, highest post-COVID
“PAT margin expanded 290 basis points to 15.2%.”
Last price increase in January 2025; next price revision being evaluated for early next year
Surendran Chemmenkotil · Managing Director · p. 9
Last price increase in January 2025; next price revision being evaluated for early next year
“Lastly, on the pricing front, our last price increase was implemented in January '25, and we are currently evaluating the possibility of the next price revision maybe early next year.”
Debt and working capital
Net working capital days at 13, down from 16 in FY26
Sameer Patel · Chief Financial Officer · p. 10
Net working capital days at 13, down from 16 in FY26
“our net working capital days stood at 13 days compared to 16 days in FY26.”
Cash and liquid investments Rs 348 crore at 30 Sep 2026, up from Rs 203 crore in March
Sameer Patel · Chief Financial Officer · p. 10
Cash and liquid investments Rs 348 crore at 30 Sep 2026, up from Rs 203 crore in March
“Our cash and liquid investments stood at INR348 crores as on 30th September 2026 compared to INR203 crores as on 31st March 2026, building a strong cash position to fund further our organic and inorganic growth.”
Acquisitions and new business
Specialty: 43 specialty and super specialty tests added in H1
Surendran Chemmenkotil · Managing Director · p. 8
Specialty: 43 specialty and super specialty tests added in H1
“We added 43 specialty and super specialty tests in the first half of the year, giving us further headroom for growth.”
Core Diagnostics: IRR on Core acquisition estimated at about 13% in past year, to accelerate in H2
Ameera Shah · Chairperson and Whole · p. 6
Core Diagnostics: IRR on Core acquisition estimated at about 13% in past year, to accelerate in H2
“Taking into account the acceleration of our genomics business, we estimate that in the past year, our IRR on the Core acquisition is at about 13%, and this will only accelerate in H2 as revenue growth increases and margins expand.”
Core Diagnostics: Core Diagnostics had double-digit margin last quarter
Surendran Chemmenkotil · Managing Director · Q&A · p. 17
Core Diagnostics: Core Diagnostics had double-digit margin last quarter
“So we had a double-digit margin in the last quarter for Core Diagnostics.”
Core Diagnostics: Core was at breakeven at acquisition 1.5 years ago, now near double-digit margins
Ameera Shah · Chairperson and Whole · p. 6
Core Diagnostics: Core was at breakeven at acquisition 1.5 years ago, now near double-digit margins
“On margins, Core was at breakeven when we acquired it 1.5 years ago, and today, it is delivering near double-digit margins.”
DAPIC, Scientific: DAPIC and Scientific growing in line with company, margins above company level
Ameera Shah · Chairperson and Whole · p. 6
DAPIC, Scientific: DAPIC and Scientific growing in line with company, margins above company level
“DAPIC in Dehradun and Scientific in Agra are both growing in line with the company average, while delivering margins higher than the overall company margins, which validates both our selection and our integration approach.”
Dividends and buybacks
Interim dividend of Rs 1 per share declared
Ameera Shah · Chairperson and Whole · p. 7
Interim dividend of Rs 1 per share declared
“But before that, I just want to announce that the company has declared an interim dividend of INR1 per share.”
Management
Core Diagnostics: Planned restructuring of Core team completed
Ameera Shah · Chairperson and Whole · p. 6
Core Diagnostics: Planned restructuring of Core team completed
“We have also completed a planned restructuring of the Core team.”
Risks
Q2 monsoon among weakest in 2 decades, rainfall about 13% below normal
Ameera Shah · Chairperson and Whole · p. 3
Q2 monsoon among weakest in 2 decades, rainfall about 13% below normal
“It's also worth noting that we delivered this growth in a quarter where the monsoon was one of the weakest in over 2 decades, with rainfall about 13% below normal and highly uneven across regions.”
Hospital drug price caps have no bearing on the business
Ameera Shah · Chairperson and Whole · p. 4
Hospital drug price caps have no bearing on the business
“Let me be clear that this has no bearing on our business, either financially or operationally.”
No move towards price capping or price parity in diagnostics
Ameera Shah · Chairperson and Whole · p. 4
No move towards price capping or price parity in diagnostics
“They do not extend to diagnostics, and there is no move towards price capping or price parity in our segment.”
Other
H1 FY27 revenue grew 16.2%, ahead of stated guidance
Ameera Shah · Chairperson and Whole · p. 3
H1 FY27 revenue grew 16.2%, ahead of stated guidance
“However, over the last 4 to 6 quarters, we have stepped that up to 15% to 16% with revenue growing at 16.2% for H1 FY27, ahead of our stated guidance.”
Q2 FY27 revenue Rs 497 crore, up 16%; patient volumes up 10%, test volumes up 11%
Sameer Patel · Chief Financial Officer · p. 10
Q2 FY27 revenue Rs 497 crore, up 16%; patient volumes up 10%, test volumes up 11%
“Quarter 2 FY27 revenue stood at INR497 crores with a growth of 16% year-on-year, supported by 10% growth in patient volumes and 11% growth in test volumes.”
CGHS revenue contribution minimal; growth purely volume and mix based
Surendran Chemmenkotil · Managing Director · p. 7
CGHS revenue contribution minimal; growth purely volume and mix based
“Our revenue contribution from CGHS is minimal, so our growth has been purely volume and mix based.”
Evolving regulation, including NMC remote report authorisation, seen as a tailwind
Ameera Shah · Chairperson and Whole · p. 5
Evolving regulation, including NMC remote report authorisation, seen as a tailwind
“Taken together, we see the evolving regulatory landscape as a clear tailwind.”
H2 rollout of new CRM, dynamic pricing engine, sales app and SLIMS integration
Surendran Chemmenkotil · Managing Director · p. 9
H2 rollout of new CRM, dynamic pricing engine, sales app and SLIMS integration
“We will be rolling out a new CRM platform, a dynamic pricing engine and new sales app for our field teams and an enhanced SLIMS integration capabilities across our laboratories.”
Sources
- Earnings call transcript, Q2 FY27 Filed 10 Nov 2026 · 20 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

